Web2 dec. 2024 · LIVTENCITY (maribavir), an orally bioavailable anti-CMV compound, is the first and only antiviral agent that targets and inhibits the pUL97 protein kinase and its natural substrates. 1 It is approved in the U.S. for the treatment of adults and pediatric patients (12 years of age or older and weighing at least 35 kg) with post-transplant cytomegalovirus … Web1 jun. 2012 · Be receiving any other anti-CMV agent(s). Have a current CMV infection that is considered resistant or refractory due to inadequate adherence to prior oral anti-CMV treatment. Have severe vomiting, diarrhea, or other severe gastrointestinal illness within 24 hours prior to the time of enrollment. Have severe hepatic impairment.
Maribavir on Cytomegalovirus (CMV) - Clinical Trials Registry
Web6 jan. 2024 · The committee will discuss new drug application (NDA) 215596, for maribavir oral tablets, submitted by Takeda Pharmaceuticals USA, Inc., for the treatment of adults … Web29 sep. 2016 · The main aim of the study is to check if the cytomegalovirus infection can no longer be detected after treatment with marivabir or valganciclovir. Participants will take 2 tablets of marivabir or valganciclovir and 2 tablets of placebo twice a day for 8 weeks. safaris phenology
Antimicrobial Drugs Advisory Committee Meeting Announcement
Web2 dec. 2024 · Maribavir has multimodal anti-cytomegalovirus activity through the inhibition of UL97 protein kinase. Methods In this phase 3, open-label study, hematopoietic-cell … Web开馆时间:周一至周日7:00-22:30 周五 7:00-12:00; 我的图书馆 Web21 mei 2024 · Maribavir is an investigational treatment that has not been approved for use by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) or … safariworldimage.com